NIHR cancer research expenditure has risen from £101 million in 2010/11 to £137 million in 2016/17. This constitutes the largest investment in a disease area.
The NIHR spent approximately £1.26 million on neuroblastoma research in financial year 2016/17.
NIHR welcomes funding applications for research into any aspect of human health. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.